Skip to content
Open access

EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study

Oct 2026 · HemaSphere · Vol 10 · 0 citations · 22 references
Medicine

TL;DR

Follicular lymphoma is the most common indolent lymphoma and next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D, CREBBP, and EZH2 ).

Abstract

Follicular lymphoma (FL) is the most common indolent lymphoma, 1,2 a biologically and clinically heterogeneous entity with a diverse genetic landscape and characterized by slowly progressive but relapsing clinical course. 3 The t(14;18) translocation driving BCL ‐ 2 overexpression is present in 85% – 90% of patients 4 although additional genetic events are required for lymphomagenesis. Next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D , CREBBP , and EZH2 ). 5,6 EZH2 encodes the catalytic subunit of the Polycomb repressor complex 2 and mediates H3K27 methylation. Missense mutations in EZH2

Read PDF

Similar papers

Open access Sep 2026

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

CD20, encoded by MS4A1 , is one of the earliest and most extensively used immunotherapeutic targets in B ‐ cell malignancies and the mechanisms underlying resistance remain poorly understood.

A. Guijosa, N. Tsakmaklis, S. Dhe-Paganon et al. · 0 citations
Open access Sep 2026

CALR-mutated myeloproliferative neoplasms: Refining molecular risk beyond the driver.

Long-term data is provided across essential thrombocythaemia, post-ET myelofibrosis and primary MF, highlighting the prognostic relevance of additional somatic mutations in CALR-mutated myeloproliferative neoplasms.

G. G. Loscocco · 0 citations
Open access Oct 2026

Frontline inotuzumab ozogamicin in older adults with Philadelphia chromosome-negative B-ALL: an exploratory pooled analysis of efficacy and safety

Older adults (aged ≥ 55 years) with Philadelphia chromosome-neg-ative B-cell acute lymphoblastic leukemia (B-ALL) frequently present with adverse cytogenetic features, poor treatment tolerance, and inferior long-term outcomes [1, 2]. While intensive chemotherapy remains the standard first-line approach, its clinical ef...

Kai-Hang Shi, Jing Zhou, Gao-Xiang Wang · 0 citations
Oct 2026

Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET-Negative, HRAS-, and NF1-Mutated Metastatic Medullary Thyroid Carcinoma

Background: Selpercatinib is approved for RET-mutated medullary thyroid carcinoma (MTC); its activity in tumors without detectable RET alterations is uncertain. Patient Findings: A 50-year-old woman developed rapidly progressive MTC (Ki-67 = 30%) with extensive liver and bone metastases. Because of severe symptomatic p...

A. Alzahrani, Allianah D. Benito, B. Alghamdi et al. · 0 citations
Open access Oct 2026

Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL

L. Wang, K. Zhou, Fei Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.